Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 772 of 5804
-
Lung cancer trial tests olaparib as maintenance therapy
Disease control CompletedThe current study will compare pembrolizumab (MK-3475) plus maintenance olaparib, versus (vs) pembrolizumab plus maintenance pemetrexed for the treatment of non-squamous NSCLC. The study's 2 primary hypotheses are: 1. Pembrolizumab plus maintenance olaparib is superior to pembrol…
Phase: PHASE3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
New drug combo takes aim at brain lymphoma
Disease control OngoingBackground: Secondary central nervous system lymphoma (sCNSL) is cancer that has spread to the central nervous system. Most drugs used to treat it do not cross the blood-brain barrier. This makes it hard to treat. Researchers hope that a new combination of drugs may be able to h…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:26 UTC
-
Real-World study shows cemiplimab effective for advanced skin cancer
Disease control CompletedThe objectives of the study are: * To describe the effectiveness of cemiplimab 350 mg administered every 3 weeks (Q3W) for treatment of patients with advanced (defined as locally advanced or metastatic \[nodal or distant\]) cutaneous squamous cell carcinoma (CSCC) and patients w…
Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
Proton beam vs. X-Ray radiation: which is better for esophageal cancer?
Disease control Recruiting nowThis trial studies how well proton beam radiation therapy compared with intensity modulated photon radiotherapy works in treating patients with stage I-IVA esophageal cancer. Proton beam radiation therapy uses a beam of protons (rather than x-rays) to send radiation inside the bo…
Phase: PHASE3 • Sponsor: NRG Oncology • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Immunotherapy boost may wipe out stubborn leukemia cells
Disease control OngoingThis phase II trial studies how well pembrolizumab and dasatinib, imatinib mesylate, or nilotinib work in treating patients with chronic myeloid leukemia and persistent detection of minimal residual disease, defined as the levels of a gene product called bcr-abl in the blood. Mon…
Phase: PHASE2 • Sponsor: ECOG-ACRIN Cancer Research Group • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC
-
New implant lets heart patients check pressure from home
Disease control OngoingThis is a prospective, multi-center, open-label, single-arm CE-Mark trial to assess device safety and efficacy of the Cordella PA Sensor System in up to 75 New York Heart Association (NYHA) Class III Heart Failure patients who will receive the Cordella PA Sensor Implant.
Phase: NA • Sponsor: Endotronix, Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
New CAR-T therapy shows promise for Hard-to-Treat blood cancers
Disease control OngoingThis is a phase I/II study to evaluate the feasibility, safety and preliminary antitumor efficacy of rapcabtagene autoleucel (also known as YTB323). Rapcabtagene autoleucel will be investigated in combination with ibrutinib in chronic lymphocytic leukemia (CLL)/small lymphocytic …
Phase: PHASE1, PHASE2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
New antibody drug shows promise for Hard-to-Treat blood cancer
Disease control OngoingThis is a phase 1, open-label study evaluating the safety, clinical pharmacology and clinical activity of TNB-383B, a BCMA x CD3 T-cell engaging bispecific antibody, in participants with relapsed or refractory MM who have received at least 3 prior lines of therapy. The study cons…
Phase: PHASE1, PHASE2 • Sponsor: AbbVie • Aim: Disease control
Last updated Jun 27, 2026 09:02 UTC
-
New combo aims to control advanced colon cancer
Disease control OngoingThis phase I/II studies the side effects and best dose of regorafenib when given together with pembrolizumab in treating participants with colorectal cancer that has spread to other places in the body. Drugs used in chemotherapy, such as regorafenib, work in different ways to sto…
Phase: PHASE1, PHASE2 • Sponsor: University of Southern California • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New hope for kidney cancer: Two-Drug combo shows promise in phase 3 trial
Disease control OngoingThe purpose of this study is to test the effectiveness and safety of nivolumab combined with ipilimumab compared to nivolumab monotherapy in participants with previously untreated kidney cancer that has spread.
Phase: PHASE3 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
New combo therapy for lung cancer shows promise in early trial
Disease control CompletedBuilding upon the clinical experience of the investigators with the magnetic resonance (MR)-guided radiation therapy system and applying principals of hypofractionation toward the current treatment paradigm of concurrent chemoradiation and consolidation immunotherapy for locally …
Phase: PHASE2 • Sponsor: Washington University School of Medicine • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
Could a single shot stop deadly meningitis in HIV patients?
Disease control Recruiting nowThis will be a randomized controlled trial of asymptomatic (Cryptococcal Antigen test)CrAg positive persons in Uganda. Patients will be randomized to receive preemptive treatment with 1 dose of liposomal amphotericin (10mg/kg) in addition to standard of care fluconazole therapy.…
Phase: PHASE2, PHASE3 • Sponsor: Makerere University • Aim: Disease control
Last updated Jun 27, 2026 12:25 UTC
-
Drug cocktail aims to tame advanced leukemia
Disease control CompletedThis project is strategy aiming to improve the survival of patients with chronic myelogenous leukemia in advanced phase and myeloid blast crisis. The basis of this strategy is to add the demethylating agent 5-Azacitidine to the tyrosine kinase inhibitor ponatinib and evaluate it…
Phase: PHASE2 • Sponsor: Versailles Hospital • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
Shocking bladder trouble away: nerve zap trial for spinal injury patients
Disease control Recruiting nowMost patients with spinal cord injury (SCI) develop neurogenic lower urinary tract dysfunction (NLUTD), one of the most devastating sequelae of SCI which ultimately can lead to renal failure. We urgently need an intervention that prevents NLUTD before irreversible damage occurs. …
Phase: NA • Sponsor: University of Zurich • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
Engineered immune cells take on childhood cancers in first human test
Disease control OngoingThis is a phase I, open-label, non-randomized study that will enroll pediatric and young adult research participants with relapsed or refractory non-CNS solid tumors to evaluate the safety, feasibility, and efficacy of administering T cell products derived from the research parti…
Phase: PHASE1 • Sponsor: Seattle Children's Hospital • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC
-
New drug cocktail aims to wipe out breast cancer before surgery
Disease control OngoingThis is a prospective, open label study to evaluate the efficacy and safety of neoadjuvant pyrotinib in early breast cancer patients.
Phase: PHASE2 • Sponsor: RenJi Hospital • Aim: Disease control
Last updated Jun 26, 2026 16:19 UTC
-
Could 2 HPV vaccine doses be enough? new study says maybe.
⭐️ VACCINE ⭐️ CompletedThe investigators are evaluating whether 15-26 year old males and females need a 3rd dose of the human papillomavirus (HPV) vaccine, or whether 2 doses provide similar protection as 3 doses from the 9 types of HPV that it protects against.
Phase: PHASE4 • Sponsor: The University of Texas Medical Branch, Galveston • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 12:08 UTC
-
New drug combo shows promise in halting advanced skin cancer
Disease control OngoingThis phase II trial studies how well avelumab with or without cetuximab work in treating patients with skin squamous cell cancer that has spread to other places in the body. Immunotherapy with monoclonal antibodies, such as avelumab and cetuximab, may help the body's immune syste…
Phase: PHASE2 • Sponsor: Alliance for Clinical Trials in Oncology • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
Could antibody shots replace daily HIV pills for kids?
Disease control CompletedThe purpose of this study is to evaluate the impact of two broadly neutralizing antibodies, VRC01LS and 10-1074, on the maintenance of HIV suppression in a cohort of early-treated children in Botswana.
Phase: PHASE1, PHASE2 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC
-
Blood filtering treatment tested for sudden liver failure
Disease control TerminatedThis is a Phase 3, multicenter, randomized, controlled, parallel-group, open-label study to evaluate the effects of plasma exchange using human serum albumin 5% (PE-A 5%) in acute-on-chronic liver failure (ACLF) subjects. The study will involve approximately 40 study centers in t…
Phase: PHASE3 • Sponsor: Instituto Grifols, S.A. • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC